

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date 25-Oct-2024

To,
Department of Corporate Affairs
BSE Limited
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code - 540694

**Sub: Press Release titled "ANG Lifesciences India Limited reports an
EBIDTA of INR 49.09 Cr for H1FY22"**

Dear Sir/Madam,


We hereby attach a copy of the Press Release titled "**ANG Lifesciences India Limited reports an EBIDTA of INR 49.09 Cr for H1FY22**" issued by the Company.

We request you to kindly disseminate the above information to the shareholders.

The said information is also being made available on the website of the Company at www.anglifesciences.com

Yours Faithfully,

For **ANG Lifescience India Limited**


Renu Kaur

Company Secretary

Press Release - Financial Results H1 FY22

ANG Lifesciences India Limited reports a EBITDA of INR 51 Cr for FY22

Amritsar, Oct 25th , 2021: ANG Lifesciences India Limited (ANG), **one of the India's leading manufacturers of Finished Pharmaceutical Formulations** headquartered in Amritsar (Pb), in its board meeting held on 25th OCT 2021 has inter-alia considered and approved the Unaudited Financial Results of the Company for the Half yearly Ended on 30th Sept 2021 as one of its agenda.

Financial Highlights (Consolidated)– H1 FY22 Vs H2 FY21

Particulars (INR Cr)	H1FY22	H2FY21	HoH (%)
Revenue	215.54	68.38	315%
Gross Profit	86.51	20.01	
EBITDA	49.09	6.49	756%
EBITDA Margin %	23%	9.0%	
PAT	33.78	1.52	2221%
PAT Margin %	15.50%	2.5%	

Financial Highlights – H1 FY22 Vs H1 FY21

Particulars (INR Cr)	H1FY22	H1FY21	YoY (%)
Revenue	215.54	86.55	249%
Gross Profit	86.51	26.84	
EBITDA	49.09	9.33	526%
EBITDA Margin %	23%	11%	
PAT	33.78	5.50	614%
PAT Margin %	15.50%	6.5%	

H1 FY22 Summary:-

- Total Income up at INR 215.54 Cr, registering a growth of 249 % YoY.
- EBITDA of INR 49.09 Cr up 526 % YoY; EBITDA margin stood at 23%.
- EBITDA margin improved due to:
 - Increase in sale of high margin products and Continuous Focus on Exports.
 - Better financial control and monitoring of other administrative expenses.
 - Improvement in the ratio of manufacturing cost overheads as percentage of sale.
- Reported PAT of INR 33.78 Cr, registering a growth of 614% YoY ; NPM stood at 15.5%
- The Board of Directors of the Company in its meeting held today approved an Interim Dividend of Rs.1/- per equity share of Rs.10/- each (10%).
- EPS at ₹32.60 Rs Per share as compared to ₹ 5.55 YoY; a Growth of 587%.

Management Comments

Commenting on the performance of H1 FY22, Mr. Rajesh Gupta, Chairman & Managing Director, ANG Lifesciences India Limited said:

“This half yearly was embarked with great macro challenges, deceleration of economic activity and other issues related to logistics and supply of raw materials. Despite all these hurdles, ANG has been able to achieve stupendous topline growth, mainly driven by demand surge in all our key products with healthy order book from domestic and Multifold Rise in Export orders. Our efforts on product rationalization, focus on high margin products, cost control initiatives and improvement in operational matrix with better supply chain management have yielded results. The margins have improved significantly more than double from last year, mainly because of acquisitions and higher realizations in the Formulations. We have been striving continuously in pushing our Formulations business and thus have been spending extensively on acquisition’s and promoting our own brands through domestic branding. ANG’s wide range of basket of 1000+ formulations, and non-dependence on any one formulation helped us to clock a turnover of INR 215.54 Cr which includes just 10% of Covid portfolio. We will continue to launch new Formulations in coming times like Complex Steroids, Hormones and Anti-Retro Viral and to include wide range of Oncology products.

The board has approved an Interim Dividend @ 10% per Equity Shares of face value of Rs. 10/-, which translates to Rs. 1 per equity share.

Going forward, we are confident to post similar performance, owing to healthy order book from domestic as well as Export and new launches, high demand and realization from existing key products and commencement of operations of our future plant by end of FY22.”

About ANG Lifesciences India Limited:

ANG Life science India limited is a leading pharmaceutical company engaged in the business of manufacturing and marketing of finished pharmaceutical formulations across all dosage forms. The company has geographical presence across India, Africa, Latin America, Gulf Countries & ROW etc . Presently, **the company owns and operates 7 state of the art manufacturing facilities & manufactures over 1000+ formulations** at Baddi (H.P). These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities.

Forward-Looking Statement:

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward- looking statements. ANG Lifesciences India Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact

Renu Kaur Company Secretary Email: cs@anglifesciences.com
